Stockscreener 앱 받기
118.97
0.42%
-0.50
시간 외 거래:
119.30
0.33
+0.28%
Sarepta Therapeutics Inc 주식(SRPT)의 최신 뉴스
Nippon Owes $115M In Muscular Dystrophy IP Fight, Jury Says - Law360
Nippon Shinyaku Owes Sarepta $115 Million on Gene-Therapy Patent - Bloomberg Law
Sarepta Wins First Phase of Nippon Shinyaku Gene-Therapy Trial - Bloomberg Law
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder - MSN
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam - Yahoo Finance
Communiqué de presse - GlobeNewswire Inc.
Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trial - Yahoo Finance
Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright - MarketBeat
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts - Benzinga
Even though Sarepta Therapeutics (NASDAQ:SRPT) has lost US$491m market cap in last 7 days, shareholders are still up 33% over 1 year - Simply Wall St
Sarepta Completes Pivotal Phase 3 Trial Enrollment for Groundbreaking Muscular Dystrophy Gene Therapy - StockTitan
National Bank of Canada FI Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Sells $1,310,820.00 in Stock - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Geode Capital Management LLC - MarketBeat
Stifel Financial Corp Grows Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics' SWOT analysis: DMD leader's stock poised for growth - Investing.com
19,358 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bought by World Investment Advisors LLC - MarketBeat
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Yahoo Finance
Garden State Investment Advisory Services LLC Buys Shares of 16,936 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst - Benzinga
FDA’s new accelerated approval guidance to benefit rare disease drug development, analysts believe - Proactive Investors USA
Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High? - Yahoo Finance
Y Intercept Hong Kong Ltd Sells 29,809 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
HighTower Advisors LLC Sells 10,327 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Two Sigma Advisers LP Lowers Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Point72 Asset Management L.P. Cuts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Main Management ETF Advisors LLC Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Wellington Management Group LLP Purchases 665,087 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Kathryn Jean Boor Sells 1,636 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock - MarketBeat
Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report? - MSN
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sarepta therapeutics director sells $205,399 in stock - Investing.com India
Sarepta therapeutics director sells $205,399 in stock By Investing.com - Investing.com Nigeria
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Soros Fund Management LLC Acquires Shares of 206,583 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Duchenne Muscular Dystrophy Pipeline Insights 2024: - openPR
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 33,278 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta, Biotech’s Regulatory Go-Getter, Signs Standout Rare Disease Deal - BioSpace
The Manufacturers Life Insurance Company Has $9.34 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta to develop Arrowhead’s muscular dystrophy treatments - Muscular Dystrophy News
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing… - MSN
Sarepta gains rights to Arrowhead Huntington’s treatment candidate - Huntington's Disease News
Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock poised for growth - Investing.com
Edgestream Partners L.P. Takes $2.31 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Zacks Research Has Positive Forecast for SRPT Q1 Earnings - MarketBeat
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? - Benzinga
Erste Asset Management GmbH Purchases Shares of 636,065 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Bellevue Group AG - MarketBeat
Point72 Europe London LLP Invests $872,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Braidwell LP Sells 42,777,500 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock? - MSN
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Eventide Asset Management LLC - MarketBeat
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz Strong - MSN
Sarepta Therapeutics Awards 8,040 RSUs to New Employees in Latest Hiring Push - StockTitan
2.88%
2.65%
자본화:
|
볼륨(24시간):